 |
|
|
| |
Long-term Follow-up of Patients Treated with Boceprevir in Combination with PEG-Intron/Ribavirin (P/R): Durability of Responses and Rates of Reversion of Resistance Mutations
|
| |
| |
Reported by Jules Levin
International HIV and Hepatitis Drug Resistance Workshop, June 8-12, 2010,
Dubrovnik, Croatia
R. Ralston, J. Vierling, E. Lawitz, J. McCone, S. Gordon, D. Pound,
M. Davis, J. Galati, I. Jacobson, L. Rossaro, F. Anderson, J. King,
W. Cassidy, M. Bourliere, R. Esteban-Mur, N. Ravendhran,
G. Galler, J. Long, N. Boparai, P. Mendez, C. Brass, J. Albrecht
Supported by Schering-Plough Corporation, now Merck & Co. Inc., Whitehouse Station, N.J., U.S.A.
This information is property of Merck, used only with permission.
|
| |
|
|
|
|
|
